Cancer Letters
Volume 258, Issue 2 , Pages 215-222 , 18 December 2007

Receptor EphA2 activation with ephrinA1 suppresses growth of malignant mesothelioma (MM)

Received 26 June 2007 ,Revised 6 September 2007 ,Accepted 10 September 2007.

References 

  1. Jin ML, Li X, Luo J, Zhao HY, Liu Y. Relationship between the malignant mesothelioma and simian virus 40 in China: a study of 17 cases. Zhonghua Bing Li Xue Za Zhi. 2006;35:602–605
  2. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366:397–408
  3. Reid A, Berry G, de Klerk N, Hansen J, Heyworth J, Ambrosini G, et al. Age and sex differences in malignant mesothelioma after residential exposure to blue asbestos (crocidolite). Chest. 2007;131:376–382
  4. Pass HI, Vogelzang N, Hahn S, Carbone M. Malignant pleural mesothelioma. Curr. Probl. Cancer. 2004;28:93–174
  5. Versnel MA, Claesson-Welsh L, Hammacher A, Bouts MJ, van der Kwast TH, Eriksson A, et al Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors. Oncogene. 1991;6:2005–2011
  6. Dazzi H, Hasleton PS, Thatcher N, Wilkes S, Swindell R, Chatterjee AK. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br. J. Cancer. 1990;61:924–926
  7. Nasreen N, Mohammed KA, Antony VB. Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells. Cancer. 2006;107:2425–2435
  8. Thirkettle I, Harvey P, Hasleton PS, Ball RY, Warn RM. Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas. Histopathology. 2000;36:522–528
  9. Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J. Pathol. 2001;193:468–475
  10. Kuhnen C, Tolnay E, Steinau HU, Voss B, Muller KM. Expression of c-Met receptor and hepatocyte growth factor/scatter factor in synovial sarcoma and epithelioid sarcoma. Virchows Arch. 1998;432:337–342
  11. Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, et al. EphB4 expression and biological significance in prostate cancer. Cancer Res. 2005;65:4623–4632
  12. Pasquale EB. The Eph family of receptors. Curr. Opin. Cell. Biol. 1997;9:608–615
  13. Himanen JP, Chumley MJ, Lackmann M, Li C, Barton WA, Jeffrey PD, et al. Repelling class discrimination: ephrin-A5 binds to and activates EphB2 receptor signaling. Nat. Neurosci. 2004;7:501–509
  14. Kinch MS, Moore MB, Harpole DH. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin. Cancer Res. 2003;9:613–618
  15. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res. 2001;61:2301–2306
  16. Walker-Daniels J, Coffman K, Azimi M, Rhim JS, Bostwick DG, Snyder P, et al. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate. 1999;41:275–280
  17. Easty DJ, Herlyn M, Bennett DC. Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis. Int. J. Cancer. 1995;60:129–136
  18. Miyazaki T, Kato H, Fukuchi M, Nakajima M, Kuwano H. EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int. J. Cancer. 2003;103:657–663
  19. Noblitt LW, Bangari DS, Shukla S, Knapp DW, Mohammed S, Kinch MS, et al. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Ther. 2004;11:757–766
  20. Nakamura R, Kataoka H, Sato N, Kanamori M, Ihara M, Igarashi H, et al. EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci. 2005;96:42–47
  21. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness. Biochem. Biophys. Res. Commun. 2004;320:1096–1102
  22. Schlessinger J. SH2/SH3 signaling proteins. Curr. Opin. Genet. Dev. 1994;4:25–30
  23. Holland SJ, Peles E, Pawson T, Schlessinger J. Cell-contact-dependent signalling in axon growth and guidance: Eph receptor tyrosine kinases and receptor protein tyrosine phosphatase beta. Curr. Opin. Neurobiol. 1998;8:117–127
  24. Miao H, Burnett E, Kinch M, Simon E, Wang B. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat. Cell Biol. 2000;2:62–69
  25. Carter N, Nakamoto T, Hirai H, Hunter T. EphrinA1-induced cytoskeletal re-organization requires FAK and p130(cas). Nat. Cell Biol. 2002;4:565–573
  26. Miao H, Wei BR, Peehl DM, Li Q, Alexandrou T, Schelling JR, et al. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat. Cell Biol. 2001;3:527–530
  27. Pratt RL, Kinch MS. Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade. Oncogene. 2002;21:7690–7699
  28. Nasreen N, Mohammed KA, Dowling PA, Ward MJ, Galffy G, Antony VB. Talc induces apoptosis in human malignant mesothelioma cells in vitro. Am. J. Respir. Crit. Care Med. 2000;161:595–600
  29. Nasreen N, Mohammed KA, Sanders K, Hardwick J, Van Horn RD, Sriram PS, et al. Pleural mesothelial cell (PMC) defense mechanisms against malignancy. Oncol. Res. 2003;14:155–161
  30. Najmunnisa N, Mohammed KA, Brown S, Su Y, Sriram PS, Moudgil B, et al. Talc mediates angiostasis in malignant pleural effusions via endostatin induction. Eur. Respir. J. 2007;29:761–769
  31. Kinch MS, Carles-Kinch K. Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. Clin. Exp. Metastasis. 2003;20:59–68
  32. Sulman EP, Tang XX, Allen C, Biegel JA, Pleasure DE, Brodeur GM, et al. ECK, a human EPH-related gene, maps to 1p36.1, a common region of alteration in human cancers. Genomics. 1997;40:371–374
  33. Treisman R. Ternary complex factors: growth factor regulated transcriptional activators. Curr. Opin. Genet. Dev. 1994;4:96–101
  34. Pandey A, Shao H, Marks RM, Polverini PJ, Dixit VM. Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. Science. 1995;268:567–569
  35. Kiyokawa E, Takai S, Tanaka M, Iwase T, Suzuki M, Xiang YY, et al. Overexpression of ERK, an EPH family receptor protein tyrosine kinase, in various human tumors. Cancer Res. 1994;54:3645–3650
  36. Zantek ND, Azimi M, Fedor-Chaiken M, Wang B, Brackenbury R, Kinch MS. E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ. 1999;10:629–638
  37. Aliaga JC, Deschenes C, Beaulieu JF, Calvo EL, Rivard N. Requirement of the MAP kinase cascade for cell cycle progression and differentiation of human intestinal cells. Am. J. Physiol. 1999;277:G631–G641
  38. Schramek H, Schumacher M, Wilflingseder D, Oberleithner H, Pfaller W. Differential expression and activation of MAP kinases in dedifferentiated MDCK-focus cells. Am. J. Physiol. 1997;272:C383–C391
  39. Roovers K, Davey G, Zhu X, Bottazzi ME, Assoian RK. Alpha5beta1 integrin controls cyclin D1 expression by sustaining mitogen-activated protein kinase activity in growth factor-treated cells. Mol. Biol. Cell. 1999;10:3197–3204
  40. Lu Q, Smith GD, Chen DY, Han ZM, Sun QY. Activation of protein kinase C induces mitogen-activated protein kinase dephosphorylation and pronucleus formation in rat oocytes. Biol. Reprod. 2002;67:64–69
  41. Elowe S, Holland SJ, Kulkarni S, Pawson T. Downregulation of the Ras-mitogen-activated protein kinase pathway by the EphB2 receptor tyrosine kinase is required for ephrin-induced neurite retraction. Mol. Cell Biol. 2001;21:7429–7441

☆ This work was supported by NIH RO1 AI 45338-02 grant from the National Institute of Health.

PII: S0304-3835(07)00425-9

doi: 10.1016/j.canlet.2007.09.005

Cancer Letters
Volume 258, Issue 2 , Pages 215-222 , 18 December 2007

Article Tools

* Image Usage & Resolution